AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39218235 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol treatment
Number of subjects: 707
Study 39218235 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids treatment
Number of subjects: 707
Study 39218235 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 707
Study 39218309 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019
Number of subjects: 6695
Study 39218309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6695
Study 39218777 — intervention group
Group type: COMPARATOR
Intervention: Immediate soft-tissue augmentation (STA) during the same surgical procedure (Control group)
Number of subjects: 40
Study 39218777 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed soft-tissue augmentation (STA) performed 3 months later (Test group)
Number of subjects: 40
Study 39218777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 39218855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Number of subjects: 0
Study 39218875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormonal therapy (GAHT) for 12 weeks
Number of subjects: 36
Study 39218883 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban school-based WASH programme (Project WISE)
Number of subjects: 6229
Study 39218883 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 6229
Study 39218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose chemotherapy (RDC) followed by blinatumomab for 2 weeks
Number of subjects: 35
Study 39218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab extended to 4 weeks for those failing to achieve CRc
Number of subjects: 35
Study 39218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (RDC + blinatumomab)
Number of subjects: 35
Study 39218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival rates
Number of subjects: 35
Study 39218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 35
Study 39218948 — intervention group
Group type: EXPERIMENTAL
Intervention: mFCCA short version
Number of subjects: 318
Study 39218965 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest SBP group
Number of subjects: 2845
Study 39218965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest SBP group
Number of subjects: 2845
Study 39218965 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP categories
Number of subjects: 2845
Study 39218965 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP categories
Number of subjects: 2845
Study 39218965 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal BP levels
Number of subjects: 2845
Study 39219163 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 224
Study 39219163 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 224
Study 39219192 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for HCV
Number of subjects: 0
Study 39219209 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMHs)
Number of subjects: 1352
Study 39219209 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cerebral microbleeds (CMBs)
Number of subjects: 1352
Study 39219209 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cerebral microbleeds (CMBs)
Number of subjects: 1352
Study 39219209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar infarction
Number of subjects: 1352
Study 39219209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diagnostic model including CVD biomarkers
Number of subjects: 1352
Study 39219320 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP; CIMZIA™)
Number of subjects: 0
Study 39219320 — intervention group
Group type: EXPERIMENTAL
Intervention: Population PK model based on data from the CHERISH study (NCT04163016)
Number of subjects: 0
Study 39219320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior information based on a population PK model for certolizumab pegol in non-pregnant adult patients (NCT04740814)
Number of subjects: 0
Study 39219437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (pooled)
Number of subjects: 7629
Study 39219437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7629
Study 39219492 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 150 mg orally once daily on an empty stomach
Number of subjects: 0
Study 39219857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal Bacillus Calmette-Guérin (BCG) injection
Number of subjects: 0
Study 39219857 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39219956 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 60
Study 39219956 — intervention group
Group type: COMPARATOR
Intervention: Sodium hypochlorite (3%)
Number of subjects: 60
Study 39219956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (940 nm)
Number of subjects: 60
Study 39219956 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (2,780 nm)
Number of subjects: 60
Study 39220267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT)
Number of subjects: 67
Study 39220267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scale (VABS-III)
Number of subjects: 67
Study 39220298 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB ≥4 mutations/Mb
Number of subjects: 388
Study 39220298 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive PD-L1 TPS (≥1%)
Number of subjects: 388
Study 39220298 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB ≥10 mutations/Mb
Number of subjects: 388
Study 39220298 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 TPS positive (≥1%)
Number of subjects: 388
Study 39220343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohnut used during sexual encounters (average 72.4% of encounters)
Number of subjects: 31
Study 39220343 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no Ohnut used)
Number of subjects: 31
Study 39220343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohnut acceptability questionnaire
Number of subjects: 31
Study 39220573 — intervention group
Group type: EXPERIMENTAL
Intervention: CM310 300 mg subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and 300 mg CM310 Q2W for a total of 14 doses during the maintenance period.
Number of subjects: 180
Study 39220573 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and placebo Q2W for a total of 14 doses during the maintenance period.
Number of subjects: 180
Study 39220578 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Transmission (QT) Scan
Number of subjects: 430
Study 39220578 — intervention group
Group type: COMPARATOR
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 430
Study 39220658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Number of subjects: 38
Study 39220658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 39220734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS with HABIT-ILE training
Number of subjects: 44
Study 39220734 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS with HABIT-ILE training
Number of subjects: 44
Study 39221160 — intervention group
Group type: EXPERIMENTAL
Intervention: UNISALUD intervention (11 sessions with interactive elements such as videos, audio, and infographics)
Number of subjects: 176
Study 39221160 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list, treatment after 27 days)
Number of subjects: 176
Study 39221228 — intervention group
Group type: EXPERIMENTAL
Intervention: DESIRE intervention (training programme for health professionals, patient decision aid, kidney service consultation)
Number of subjects: 27
Study 39221228 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study 39221451 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 0
Study 39221451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39221503 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB graft
Number of subjects: 114
Study 39221503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft
Number of subjects: 114
Study 39221503 — intervention group
Group type: COMPARATOR
Intervention: BPTB graft and Hamstring tendon graft
Number of subjects: 114
Study 39221516 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 245
Study 39221516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 39221566 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study 39221566 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 0
Study 39221567 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-COVID
Number of subjects: 51
Study 39221567 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 51
Study 39221567 — intervention group
Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 51
Study 39221611 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 357
Study 39221611 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 357
Study 39221611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 39221629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation with cryoablation (n=64)
Number of subjects: 126
Study 39221629 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure with phrenic nerve pacing (n=62)
Number of subjects: 126
Study 39221651 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (6 g, four weekly infusions)
Number of subjects: 18219
Study 39221651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18219
Study 39221769 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivoxel neuroreinforcement (1, 3, or 5 sessions)
Number of subjects: 23
Study 39221769 — intervention group
Group type: COMPARATOR
Intervention: Control phobia (not specified)
Number of subjects: 23
Study 39221824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (n=56) for 56 weeks
Number of subjects: 112
Study 39221824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=52) transitioned to Mavacamten from weeks 16 to 56 (40-week exposure)
Number of subjects: 112
Study 39222035 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide for 3 months (150 mg once daily in a sustained-release dose)
Number of subjects: 186
Study 39222035 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide for 6 months (150 mg once daily in a sustained-release dose)
Number of subjects: 186
Study 39222035 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no additional treatment for 6 months)
Number of subjects: 186
Study 39222182 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TAF-based PrEP
Number of subjects: 30
Study 39222182 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PrEP/STI services
Number of subjects: 30
Study 39222277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 256
Study 39222277 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 256
Study 39222277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 256
Study 39222277 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 256
Study 39222281 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry in patients with HF
Number of subjects: 151
Study 39222281 — intervention group
Group type: COMPARATOR
Intervention: Accelerometry in healthy controls
Number of subjects: 151
Study 39222281 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA) in healthy controls
Number of subjects: 151
Study 39222281 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) in patients with HF
Number of subjects: 151
Study 39222281 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of average acceleration with 6-minute walking test (6MWT) in patients with HF
Number of subjects: 151
Study 39222281 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of average acceleration with maximal oxygen uptake in patients with HF
Number of subjects: 151
Study 39222281 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of accelerometer measurements with LVEF in patients with HF
Number of subjects: 151
Study 39222281 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of accelerometer measurements with NT-proBNP in patients with HF
Number of subjects: 151
Study 39222348 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 18
Study 39222348 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 18
Study 39222348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription Digital Therapeutics (PDT)
Number of subjects: 18
Study 39222348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal Use (Fidelity)
Number of subjects: 18
Study 39222391 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral preparation
Number of subjects: 40
Study 39222391 — intervention group
Group type: COMPARATOR
Intervention: Rectal enema
Number of subjects: 40
Study 39222391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (oral preparation and rectal enema)
Number of subjects: 40
Study 39222408 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 0
Study 39222408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39222436 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 907
Study 39222436 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 907
Study 39222437 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD)
Number of subjects: 20
Study 39222513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult ICT
Number of subjects: 3761
Study 39222513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosure iFOB
Number of subjects: 3761
Study 39222513 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-Light S FIT
Number of subjects: 3761
Study 39222513 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickVue iFOB
Number of subjects: 3761
Study 39222513 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-Auto FIT (threshold >100 ng/mL)
Number of subjects: 3761
Study 39222513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 3761
Study 39222579 — intervention group
Group type: EXPERIMENTAL
Intervention: CatBoost classifier
Number of subjects: 48
Study 39222579 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest classifier
Number of subjects: 48
Study 39222579 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine classifier
Number of subjects: 48
Study 39222579 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline acoustic and MFCC features
Number of subjects: 48
Study 39222642 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg in SELECT, STEP-HFpEF, and STEP-HFpEF DM; 1.0 mg in FLOW)
Number of subjects: 3743
Study 39222649 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg twice daily
Number of subjects: 375
Study 39222649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 39222687 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 oz beef patty
Number of subjects: 0
Study 39222687 — intervention group
Group type: COMPARATOR
Intervention: 4 oz SBMA
Number of subjects: 0
Study 39222687 — intervention group
Group type: COMPARATOR
Intervention: 8 oz SBMA
Number of subjects: 0
Study 39222701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel
Number of subjects: 2559
Study 39222701 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2559
Study 39222701 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 2559
Study 39222737 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0
Study 39222737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39222896 — intervention group
Group type: EXPERIMENTAL
Intervention: TEER group (TriClip System + medical therapy)
Number of subjects: 572
Study 39222896 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical therapy alone)
Number of subjects: 572
Study 39222964 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT Diary (automated directly observed therapy app)
Number of subjects: 100
Study 39222964 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (control)
Number of subjects: 100
Study 39223284 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-guided screening using a digital stethoscope
Number of subjects: 1232
Study 39223284 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead AI-electrocardiogram model
Number of subjects: 1232
Study 39223284 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1232
Study 39223302 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation of carbon dioxide (CO2) during laparoscopic surgery, specific dosage and duration not mentioned
Number of subjects: 0
Study 39223359 — intervention group
Group type: EXPERIMENTAL
Intervention: VBM and DTI imaging
Number of subjects: 21
Study 39223359 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor deficit assessments (Nine peg hole test, dynamometer, Hand-Tapping Test)
Number of subjects: 21
Study 39223359 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal fractional anisotropy (FA)
Number of subjects: 21
Study 39223424 — intervention group
Group type: EXPERIMENTAL
Intervention: REMOTE (live video urogenital rehabilitation intervention protocol)
Number of subjects: 28
Study 39223424 — intervention group
Group type: COMPARATOR
Intervention: SELF (home-based pre-recorded video protocol)
Number of subjects: 28
Study 39223470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 204
Study 39223470 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia
Number of subjects: 204
Study 39223504 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous Zoledronic acid (ZOL)
Number of subjects: 108
Study 39223526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized N-acetylcysteine (NAC) therapy over 12 weeks
Number of subjects: 100
Study 39223545 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (3 mg/m²) plus Irinotecan
Number of subjects: 108
Study 39223593 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 223
Study 39223593 — intervention group
Group type: COMPARATOR
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 223
Study 39223596 — intervention group
Group type: EXPERIMENTAL
Intervention: JoyPop™ app (intervention)
Number of subjects: 0
Study 39223596 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 39223600 — intervention group
Group type: EXPERIMENTAL
Intervention: mhGAP-Remote (1 in-person session + 8 weeks of SMS)
Number of subjects: 0
Study 39223600 — intervention group
Group type: COMPARATOR
Intervention: mhGAP-Standard (4 to 6 in-person sessions)
Number of subjects: 0
Study 39223617 — intervention group
Group type: EXPERIMENTAL
Intervention: modified prolonged exposure therapy (mPE) + treatment as usual (TAU)
Number of subjects: 22
Study 39223617 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 22
Study 39223617 — intervention group
Group type: EXPERIMENTAL
Intervention: modified prolonged exposure therapy (mPE)
Number of subjects: 22
Study 39223657 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited fasciectomy with autologous adipose tissue grafting
Number of subjects: 150
Study 39223657 — intervention group
Group type: COMPARATOR
Intervention: Limited fasciectomy alone
Number of subjects: 150
Study 39223952 — intervention group
Group type: EXPERIMENTAL
Intervention: Indo-Mediterranean diet (IMD)
Number of subjects: 39
Study 39223952 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted diet (CRD)
Number of subjects: 39
Study 39223953 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy sessions
Number of subjects: 37
Study 39223992 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 980
Study 39224057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model with Neuromuscular Inhibition Technique (FDM with NIT)
Number of subjects: 54
Study 39224057 — intervention group
Group type: COMPARATOR
Intervention: Fascial Distortion Model alone (FDM)
Number of subjects: 54
Study 39224116 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 39224116 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 0
Study 39224138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing fresh, lean beef
Number of subjects: 17
Study 39224138 — intervention group
Group type: COMPARATOR
Intervention: Diet containing plant alternatives
Number of subjects: 17
Study 39224188 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Number of subjects: 88
Study 39224580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture therapy (PPT)
Number of subjects: 50
Study 39224580 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 50
Study 39224668 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided digital CBT-I intervention
Number of subjects: 0
Study 39224668 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39224752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation (REHAB+)
Number of subjects: 900